BioSpace News Archive

The final results of the PROTECT III and Restore EF prospective studies demonstrate improved outcomes for high-risk PCI patients with the use of Impella heart pumps .

Emmaus Life Sciences, Inc today announced it has entered into an agreement with Asembia to provide expanded patient and provider support services in order to simplify access to Endari®

Albireo Pharma, Inc. today provided a business update and reported financial results for the third quarter ended September 30, 2021.

DiaMedica Therapeutics Inc. today announced that its third quarter 2021 financial results will be released after the markets close on Wednesday, November 10th.

Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that two abstracts with new preclinical data on tasquinimod, a small molecule immunomodulator, have been accepted for presentation at the 63rd ASH Annual Meeting & Exposition in Atlanta, Georgia, December 11-14, 2021.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced that three oral and five poster presentations for the Company’s induced pluripotent stem cell product platform were accepted for presentation at the 63rd American Society of Hematology Annual Meeting and Exposition being held from December 11-14, 2021.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology Annual Meeting and Exposition.

Novan, Inc., announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, recently participated in a fireside chat hosted by Jonathan Aschoff, Ph.D., Managing Director, Senior Research Analyst at ROTH Capital Partners.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, reported financial results for the third quarter and nine months ended September 30, 2021.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will present two posters on its innate cell engagers at the 63rd American Society of Hematology Annual Meeting and Exposition.